ERBB2 and neoplasm: Ten out of the thirteen HER2 amplified tumors (77 %) were scored as strongly HER2 positive (3 +), out of which six tumors (46 %) resulted in 100 %, two tumors (15 %) in 95 %, one tumor (8 %) in 60 %, and one tumor (8 %) in 50 % strong and complete membranous staining (Fig. 4a, b).